At Johnson & Johnson, we’re advancing the science of acute myeloid leukemia (AML) to address significant unmet patient needs. We’re unveiling new data that reflects our dedication to expanding our hematology portfolio and helping to shape the future of AML care. Learn more about our efforts at #ASH24. #JNJOncology #AML